Article
Surgery
Masashi Iwasaki, Masanori Shimomura, Shunta Ishihara, Tadanori Yamaguchi, Mitsuo Kishimoto, Tsunehiro Ii, Masayoshi Inoue
Summary: This study assessed the clinical significance of minimal malignant pleural effusion (MPE) using liquid-based cytology and immunocytochemistry, and reviewed the postoperative outcomes of patients with non-small-cell lung cancer (NSCLC). The results showed that minimal MPE is associated with age, tumor ratio, and histology, and CEA immunocytochemistry offers high sensitivity for diagnosis. Surgical intervention may be considered for select NSCLC patients with minimal MPE.
Article
Critical Care Medicine
Audra J. Schwalk, David E. Ost, Sahara N. Saltijeral, Henriette De La Garza, Roberto F. Casal, Carlos A. Jimenez, Georgie A. Eapen, Jeff Lewis, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Jack Lee, Yasir Elamin, Jianjun Zhang, Jack A. Roth, Stephen Swisher, John Heymach, Horiana B. Grosu
Summary: Patients with actionable mutations and those without mutations have similar risk of recurrent malignant pleural effusion, suggesting both groups may benefit from similar definitive management approaches. Larger pleural effusion size, higher pleural fluid lactate dehydrogenase levels, and positive cytologic examination results were associated with an increased hazard of recurrence.
Article
Oncology
Chi-Lu Chiang, Chia- Shen, Hsu-Ching Huang, Han-Jhih Chang, Yu-Ting Huang, Chao-Hua Chiu
Summary: This study investigates the optimal approach for EGFR mutation testing in NSCLC patients using centrifuged effusion samples and proposes a cytology-based specimen triage. The proposed strategy improves the detection rate of EGFR mutations and provides an efficient testing strategy for patients with EGFR-mutant NSCLC.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Eiji Takeuchi, Yoshio Okano, Hisanori Machida, Katsuhiro Atagi, Yoshihiro Kondou, Naoki Kadota, Nobuo Hatakeyama, Keishi Naruse, Tsutomu Shinohara
Summary: This study retrospectively analyzed lung cancer patients with malignant pleural effusion (MPE) and found that those with eosinophilic pleural effusion (EPE) had a better prognosis than those without EPE. Factors such as EPE, Eastern Cooperative Oncology Group (ECOG) Performance Status, sex, and the neutrophil-to-lymphocyte ratio in the serum were identified as independent prognostic factors affecting survival.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Engineering, Biomedical
Zhenhuan Song, Weizhan Luo, Haichong Zheng, Yunxiang Zeng, Jinlin Wang, Tianfeng Chen
Summary: A translational selenium nanoparticles coated with immune-modulating macromolecule lentinan are designed to restore dysfunctional immune cells in patient-derived malignant pleural effusion microenvironment, enhancing immune responses and inhibiting tumor growth, thereby providing a potential therapeutic strategy for advanced lung cancer patients with MPE.
ADVANCED HEALTHCARE MATERIALS
(2021)
Article
Medicine, General & Internal
Zhangqiang Xiang, Xiangyu Deng, Wenfeng He, Qian Yang, Laichao Ni, Marzieh Dehghan Shasaltaneh, Mazaher Maghsoudloo, Gang Yang, Jingbo Wu, Saber Imani, Qinglian Wen
Summary: This study found that combined treatment with apatinib, bevacizumab, and cisplatin can prolong the survival time of mice, reduce the content of malignant pleural effusion (MPE), decrease the SUVmax of thoracic tumor tissue, down-regulate the content of VEGF and sVEGFR-2 in serum and pleural fluid, and promote the apoptosis of tumor cells. Angiogenesis and MPE formation can be inhibited by down-regulation of HIF-1 alpha, VEGF, VEGFR-2, MEK1, and MMP-2 molecular signaling pathway proteins.
ANNALS OF MEDICINE
(2022)
Article
Environmental Sciences
Kuan-Jen Bai, Shu-Chuan Ho, Shu-Chuan Ho, Cheng-Yu Tsai, Jen-Kun Chen, Chun-Nin Lee, Kang-Yun Lee, Chih-Cheng Chang, Tzu-Tao Chen, Po-Hao Feng, Kuan-Yuan Chen, Chien-Ling Su, Hsiao-Chi Chuang
Summary: The study found that PM2.5 exposure and possible Zn in pleural effusion were associated with the development of malignant pleural effusion in lung cancer patients.
ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY
(2021)
Article
Oncology
Hiroshi Nokihara, Hirokazu Ogino, Atsushi Mitsuhashi, Kensuke Kondo, Ei Ogawa, Ryohiko Ozaki, Yohei Yabuki, Hiroto Yoneda, Kenji Otsuka, Yasuhiko Nishioka
Summary: These data suggest that the efficacy of osimertinib may differ between EGFR T790M-positive and -negative NSCLC patients with PE. The presence of PE was independently associated with shorter PFS and OS in EGFR T790M-positive NSCLC patients, but not in EGFR T790M-negative patients.
Article
Oncology
Petr Makhov, Igor Bychkov, Bulat Faezov, Alexander Deneka, Alexander Kudinov, Emmanuelle Nicolas, Rohan Brebion, Eleanor Avril, Kathy Q. Cai, Leonid V. Kharin, Mark Voloshin, Elena Frantsiyants, Nikolay Karnaukhov, Oleg I. Kit, Iuliia Topchu, Rushaniya Fazliyeva, Anna S. Nikonova, Ilya G. Serebriiskii, Hossein Borghaei, Martin Edelman, Essel Dulaimi, Erica A. Golemis, Yanis Boumber
Summary: MSI2 regulates EGFR protein expression in non-small cell lung cancer, and depletion of MSI2 can affect proliferation of EGFR(mut) cells and response to EGFR-targeting drugs, suggesting inhibition of MSI2 could be clinically valuable in EGFR(mut) NSCLC.
Article
Oncology
Qingsong Li, Cheng Hu, Shengfa Su, Zhu Ma, Yichao Geng, Yinxiang Hu, Huiqin Li, Bing Lu
Summary: Actionable mutations are common in patients with non-small cell lung cancer (NSCLC) and malignant pleural effusion (MPE). The failure pattern of patients treated with targeted therapy after MPE control is unclear. This study found that 50% of patients experience failure at the initial disease sites, and radiotherapy may offer survival benefits during the course of the disease.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Ming-Fang Wu, Chih-An Lin, Tzu-Hang Yuan, Hsiang-Yuan Yeh, Sheng-Fang Su, Chin-Lin Guo, Gee-Chen Chang, Ker-Chau Li, Chao-Chi Ho, Huei-Wen Chen
Summary: The study identified the M1/M2 spectrum and plasticity of MPE-Mϕ, and described a two-gene M1/M2 signature that can predict outcomes of late-stage lung cancer patients. Furthermore, re-educating MPE-Mϕ towards anti-cancer M1 macrophages using clinically applicable strategies may overcome tumor immune escape and benefit anti-cancer therapies.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Medicine, General & Internal
Takeshi Saraya, Kosuke Ohkuma, Masachika Fujiwara, Haruyuki Ishii
Summary: Malignant mesothelioma (MM) is difficult to diagnose and it is crucial to differentiate it from lung cancer (LC) for proper treatment. This study analyzed data from 530 patients with pleural effusion and found that pleural carcinoembryonic antigen and hyaluronic acid could be used to differentiate MM from LC. These findings are important for improving diagnostic accuracy and selecting appropriate treatment methods.
Editorial Material
Critical Care Medicine
Chuan T. Foo, Anna Paterson, Adam Duckworth, Jurgen Herre
Summary: Malignant pleural effusion is common in mesothelioma, with the presence of hyaluronic acid contributing to its viscosity. Intrapleural hyaluronidase can effectively reduce fluid viscosity and drainage duration, demonstrating feasibility and safety in managing hyaluronic acid-rich viscous malignant pleural effusion.
Review
Oncology
Alex Dipper, Nick Maskell, Anna Bibby
Summary: Malignant pleural mesothelioma (MPM) presents diagnostic challenges, with ancillary diagnostic tests such as immunocytochemical markers, molecular techniques, diagnostic biomarkers, and imaging discussed in cases where histological samples are unavailable or inconclusive. While no single adjunctive test has the sensitivity and specificity to diagnose MPM in isolation, correlation of pleural fluid cytology with radiology and biomarkers can help make an MDT-consensus diagnosis when invasive tests are not feasible.
Article
Oncology
Feng-Shuang Yi, Kan Zhai, Huan-Zhong Shi
Summary: This review summarizes the composition, phenotypic characteristics, differentiation mechanisms, and recruitment of CD4(+) T cells in malignant pleural effusion (MPE), highlighting the interactions among different Th cells and their relationships with lung cancer cells or mesothelial cells. Future research should focus on expanding the landscape map of human MPE immune cells, exploring B cell immunoregulation, and investigating communication between macrophages and Th cells in MPE for advancements in diagnoses and therapeutics.
Article
Immunology
Sheng-Wei Pan, Jia-Yih Feng, Lawrence Shih-Hsin Wu, Chin-Chung Shu, Ping-Huai Wang, Jann-Yuan Wang, Hao-Chien Wang, Wei-Juin Su, Yuh-Min Chen, Chong-Jen Yu
Summary: This study found a sex-specific association between PDCD1 gene polymorphisms and the risk of MAC-LD, possibly through regulation of PD-1 expression.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Oncology
Ching-Yao Yang, Yen -Ting Lin, Li-Ju Lin, Ya-Hsuan Chang, Hsuan-Yu Chen, Yi -Pin Wang, Jin -Yuan Shih, Chong-Jen Yu, Pan-Chyr Yang
Summary: Taiwan implemented several health policies including smoking cessation, precision therapy, and LDCT screening to combat lung cancer. The nationwide cancer registry data showed that although lung cancer incidence continued to rise, the mortality rate decreased over time. The analysis of patient data from National Taiwan University Hospital revealed a significant improvement in 5-year survival, particularly in late-stage lung cancer, suggesting the importance of early detection.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Ryan J. Hartmaier, Aleksandra A. Markovets, Myung Ju Ahn, Lecia Sequist, Ji-Youn Han, Byoung Chul Cho, Helena A. Yu, Sang-We Kim, James Chih-Hsin Yang, Jong-Seok Lee, Wu-Chou Su, Dariusz M. Kowalski, Sergey Orlov, Song Ren, Paul Frewer, Xiaoling Ou, Darren A. E. Cross, Nisha Kurian, Mireille Cantarini, Pasi A. Jaenne
Summary: Combining MET inhibitor and EGFR tyrosine kinase inhibitor can overcome acquired osimertinib resistance mediated by MET. In this study, savolitinib and osimertinib combination therapy showed promising results in advanced non-small cell lung cancer patients with MET amplification and EGFR mutation who had progressed on prior EGFR-TKI treatment. The combination therapy demonstrated acceptable safety profile and improved antitumor activity.
Article
Medicine, Research & Experimental
Keng-Mao Liao, Chih-Jung Chen, Wei-Jia Luo, Chen-Wei Hsu, Sung-Liang Yu, Pan-Chyr Yang, Kang-Yi Su
Summary: With an aging population and the numerous health impacts associated with old age, there is a growing need to find effective anti-aging drugs. In this study, diphenyleneiodonium (DPI) was identified as a potential anti-aging drug that promotes mitochondrial fission. DPI was found to reduce senescence-associated beta-galactosidase positive cells and increase proliferating cells. It also downregulated cell cycle arrest genes and SASP factors. DPI treatment in mice showed reduced senescence markers and improved physical impairments.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Oncology
Chong Kin Liam, Azura Rozila Ahmad, Te-Chun Hsia, Jianying Zhou, Dong-Wan Kim, Ross Andrew Soo, Ying Cheng, Shun Lu, Sang Won Shin, James Chih-Hsin Yang, Yiping Zhang, Jun Zhao, Karin Berghoff, Rolf Bruns, Andreas Johne, Yi-Long Wu
Summary: The final analysis of the INSIGHT phase II study showed that tepotinib plus gefitinib can improve progression-free survival (PFS) and overall survival (OS) compared to chemotherapy in a subgroup of patients with MET-amplified EGFR-mutant NSCLC after progression on EGFR inhibitors.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Benjamin P. Levy, Enriqueta Felip, Martin Reck, James C. H. Yang, Federico Cappuzzo, Yasuto Yoneshima, Caicun Zhou, Siddhartha Rawat, Jingdong Xie, Priyanka Basak, Lu Xu, Jacob Sands
Summary: The TROPION-Lung08 study is a Phase III trial evaluating the safety and efficacy of Dato-DXd plus pembrolizumab versus pembrolizumab monotherapy for advanced/metastatic NSCLC patients without AGAs and with PD-L1 tumor proportion score =50%. The primary endpoints are progression-free survival and overall survival, while secondary endpoints include objective response rate, duration of response, safety, and presence of antidrug antibodies.
Article
Oncology
Zhe-Rong Zheng, Hsiu-Ying Ku, Kun-Chieh Chen, Chun-Ju Chiang, Chih-Liang Wang, Chih-Yi Chen, Chun-Ming Tsai, Ming-Shyan Huang, Chong-Jen Yu, Jin-Shing Chen, Teh-Ying Chou, Wen-Chung Lee, Chun-Chieh Wang, Tsang-Wu Liu, Jiun-Yi Hsia, Gee-Chen Chang
Summary: The relationship between smoking and ALK-tyrosine kinase inhibitors (TKIs) on overall survival (OS) of treatment-naive ALK-positive advanced lung adenocarcinoma remains unclear in real-world.
FRONTIERS IN ONCOLOGY
(2023)
Article
Medicine, General & Internal
Lun-Che Chen, Shun-Mao Yang, Shwetambara Malwade, Hao-Chun Chang, Ling-Kai Chang, Wen-Yuan Chung, Jen-Chung Ko, Chong-Jen Yu
Summary: Lung cancer, the most lethal cancer type globally, poses significant challenges in the early detection and biopsy of small peripheral pulmonary nodules (PPN). This study demonstrates the feasibility and safety of bronchoscopic biopsy of PPN using augmented fluoroscopic bronchoscopy (AFB) and cone-beam computed tomography (CBCT) guidance in a hybrid operating room (HOR). The overall diagnostic yield was high, and complications were observed in a small number of cases. These findings highlight the potential of AFB and CBCT in improving the accuracy and safety of PPN biopsy.
Review
Infectious Diseases
Chia-Hao Chang, Lih-Yu Chang, Jen-Chung Ko, Yueh-Feng Wen, Chien-Jen Chang, Li-Ta Keng, Ping-Hsien Tsou, Kai-Lun Yu, Jann-Yuan Wang, Chong-Jen Yu
Summary: This prospective cohort study investigates the incidence, risk factors, and renal outcomes of acute kidney injury (AKI) during anti-tuberculosis (TB) treatment. The study finds that older age, higher baseline estimated glomerular filtration rate (eGFR), and higher blood eosinophil count are associated with a higher risk of AKI during TB treatment. However, these complications do not impact TB treatment completion, and no permanent renal impairment occurs.
INFECTIOUS DISEASES AND THERAPY
(2023)
Article
Oncology
Zofia Piotrowska, Daniel Shao-Weng Tan, Egbert F. Smit, Alexander I. Spira, Ross A. Soo, Danny Nguyen, Victor Ho-Fun Lee, James Chih-Hsin Yang, Vamsidhar Velcheti, John M. Wrangle, Mark A. Socinski, Marianna Koczywas, John E. Janik, Jeffrey Jones, Helena Alexandra Yu
Summary: This study demonstrates that Zipalertinib has encouraging antitumor activity in heavily pretreated patients with EGFR ex20ins-mutant NSCLC, with an acceptable safety profile and low frequency of high-grade diarrhea and rash.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Hye Ryun Kim, Shunichi Sugawara, Jong-Seok Lee, Jin-Hyoung Kang, Naoki Inui, Toyoaki Hida, Ki Hyeong Lee, Tatsuya Yoshida, Hiroshi Tanaka, Cheng-Ta Yang, Makoto Nishio, Yuichiro Ohe, Tomohide Tamura, Nobuyuki Yamamoto, Chong-Jen Yu, Hiroaki Akamatsu, Shigeru Takahashi, Kazuhiko Nakagawa
Summary: ONO-4538-52/TASUKI-52 study evaluated the efficacy and safety of combining nivolumab or placebo with bevacizumab plus platinum chemotherapy for advanced nsNSCLC. Updated data showed that nivolumab plus platinum chemotherapy and bevacizumab demonstrated longer overall survival (OS) compared to the placebo combination, indicating its potential as a standard first-line treatment for advanced nsNSCLC.
Article
Oncology
Sheng-Kai Liang, Chang-Wei Wu, Ching- Chang, Li-Ta Keng, Meng-Rui Lee, Jann-Yuan Wang, Jen-Chung Ko, Wei-Yu Liao, Kuan-Yu Chen, Chao-Chi Ho, Jin-Yuan Shih, Chong-Jen Yu
Summary: This study compared the effectiveness of adjuvant oral UFT and intravenous chemotherapy in early-stage NSCLC patients after surgery and found that both treatments had comparable clinical outcomes.
Article
Respiratory System
Chun-Ta Huang, Sheng-Yuan Ruan, Feipei Lai, Jung-Yien Chien, Chong-Jen Yu
Summary: This study investigates the prognostic value of pace variability during the 6-minute walk test (6MWT) for chronic obstructive pulmonary disease (COPD) patients. The results show that COPD patients with greater pace variability during the 6MWT have a significantly higher risk of overall mortality and COPD-related hospitalizations, indicating a worse prognosis.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
(2023)
Article
Immunology
Pei -Lan Shao, Hsiao-Chen Tu, Yu-Nong Gong, Hung-Yu Shu, Ralph Kirby, Li-Yun Hsu, Hui-Yee Yeo, Han-Yueh Kuo, Yi-Chia Huang, Yung-Feng Lin, Hui-Ying Weng, Yueh-Lin Wu, Chien-Chih Chen, Tzen-Wen Chen, Kuo-Ming Lee, Chung-Guei Huang, Shin-Ru Shih, Wei J. Chen, Chen-Chi Wu, Chong -Jen Yu, Shih-Feng Tsai
Summary: Since April 2022, the Omicron variant of SARS-CoV-2 has been spreading in Taiwan, causing community outbreaks. Through high-throughput sequencing of the SARS-CoV-2 genome, the Omicron BA.2.3.7 variant was identified as a major lineage in recent outbreaks in Taiwan.
EMERGING INFECTIOUS DISEASES
(2023)
Article
Oncology
Byoung Chul Cho, Myung-Ju Ahn, Jin Hyoung Kang, Ross A. Soo, Thanyanan Reungwetwattana, James Chih-Hsin Yang, Irfan Cicin, Dong-Wan Kim, Yi-Long Wu, Shun Lu, Ki Hyeong Lee, Yong-Kek Pang, Anastasia Zimina, Chin Heng Fong, Elena Poddubskaya, Ahmet Sezer, Soon Hin How, Pongwut Danchaivijitr, Yukyung Kim, Yeji Lim, Taewon An, Hana Lee, Hae Mi Byun, Bojan Zaric
Summary: Lazertinib demonstrated significant efficacy improvement compared with gefitinib in the first-line treatment of EGFR-mutated advanced NSCLC, with a manageable safety profile. The results of this study are of great importance for improving patient outcomes and guiding clinical practice.
JOURNAL OF CLINICAL ONCOLOGY
(2023)